Sivik Global Healthcare LLC Acquires New Shares in Edwards Lifesciences Corporation $EW

Sivik Global Healthcare LLC acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 35,000 shares of the medical research company’s stock, valued at approximately $2,984,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after acquiring an additional 365,581 shares during the period. Wellington Management Group LLP increased its holdings in shares of Edwards Lifesciences by 4.9% in the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock valued at $1,617,959,000 after acquiring an additional 977,933 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after acquiring an additional 1,423,365 shares during the period. Jennison Associates LLC increased its holdings in shares of Edwards Lifesciences by 19.6% in the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after acquiring an additional 2,287,783 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after acquiring an additional 4,805,819 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

NYSE:EW opened at $80.80 on Wednesday. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The firm has a market cap of $46.59 billion, a price-to-earnings ratio of 44.16, a PEG ratio of 2.11 and a beta of 0.95. The firm’s fifty day moving average is $81.53 and its two-hundred day moving average is $81.93.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same quarter in the prior year, the firm earned $0.59 earnings per share. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

EW has been the subject of several recent analyst reports. Citigroup restated a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Truist Financial set a $89.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, February 11th. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their target price for the company from $90.00 to $100.00 in a research note on Thursday, December 18th. Evercore restated an “outperform” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Monday, January 5th. Finally, Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $95.96.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,747,975.32. The trade was a 2.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. This represents a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 74,077 shares of company stock worth $6,165,444 in the last three months. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.